PTO/SB/08a (01-08)

Approved for use through 03/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/533,025

Filing Date 04/26/2005

First Named Inventor Behr

Art Unit 1655

Examiner Name Qiuwen MI

Attorney Docket Number 41313-1004

(Use as many sheets as necessary)

Sheet 1 of 11

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Α	us- 2001/00513347	12-13-2001	Kundu, et al.	
	В	us- 2003/0077685	04-24-2003	Schmidt, et al.	
	С	us- 2003/0099631	05-29-2003	Koji, et al.	
	D	us- 2004/0234480	11-25-2004	Pauly, et al.	
	E	us- 2006/0228426	10-12-2006	Cyr	
	F	∪s-4,855,131	08-08-1989	Iris	
	G	us- 4,857,325	08-15-1989	Albeck, et al.	
	Н	us-4,923,697	05-08-1990	Albeck, et al.	
	ı	us- 5,073,545	12-17-1991	Arima, et al.	
	J	us- 5,141,741	08-25-1992	Ishida, et al.	
	К	us- 5,627,216	05-06-1997	Papadopulos	
	L	us- 5,665,367	09-09-1997	Burger, et al.	
	М	us- 5,824,320	10-20-1998	Rouillard, et al.	
	N	∪s- 5,837,224	11-17-1998	Voorhees, et al.	
	0	∪s- 5,935,809	08-10-1999	Ryan, Jr., et al.	
	Р	us-6,079,415	06-27-2000	Bernerd, et al.	
	Q	us- 6,096,711	08-01-2000	Sherman, et al.	
	R	us- 6,130,254	10-10-2000	Fisher, et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵		
	S	CA 1,298,558	04-07-1992	Rudov				
	T	CA 2,087,600	03-18-1997	D'Arrigo				
	U	CA 2,092,821	11-19-2002	Okpanyi				
	V	CA 2,185,983	04-13-2004	Kwak et al.				
**	w	CA 2,189,486	05-04-1998					

Examiner			Date	
Signature			Considered	
(

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Complete if Known Substitute for form 1449A/PTO 10/533,025 Application Number INFORMATION DISCLOSURE 04/26/2005 Filing Date STATEMENT BY APPLICANT First Named Inventor Behr Art Unit 1655 **Examiner Name** Qiuwen MI (Use as many sheets as necessary) Attorney Docket Number 41313-1004 2 11 Sheet

	U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	X	us-6,177,122	01-23-2001	Fahey, et al.				
	Y	us-6,193,975	02-27-2001	Bonte, et al.				
	Z	us-6,271,001	08-07-2001	Clarke, et al.				
	AA	us-6,307,101	10-23-2001	Campbell, et al.				
-	AB	us-6,342,208	01-29-2001	Hyldgaard, et al.				
	AC	us-6,365,630	04-02-2002	Fisher, et al.				
	AD	us-6,406,720	06-18-2002	Pauly, et al.				
	AE	us-6,432,456	08-13-2002	Mori				
	AF	us-6,676,975	01-13-2004	Whittle, et al.				
	AG	us-6,682,763	01-27-2004	Kuno, et al.				
	AH	us-6,762,280	07-13-2004	Schmidt, et al.				
	Al	us-6,764,693	07-20-2004	Smith				
	AJ	us-6,800,292	10-05-2004	Murad				
	AK	US-						
	AL	US-						
	AM	US-						
	AN	US-						
	AO	US-						

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	AP	CA 2,288,339	05-11-1998	Raskin				
	AQ	EP 1 275 372 A1	01-15-2003	Breton				
	AR	FR 2 812 544	02-08-2002	Liviero et al.				
	AS	JP 08104628	04-23-1996	Kumagai et al.				
	AT	JP 11079970	03-23-1999	Suzuki et al.				

Examiner	Date	
Signature	Considered	•
	<u>ll</u>	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

s	substitute for form 1449A/PTO		Co	Complete if Known		
			Application Number	10/533,025		
ı	NFORMATION DISC	CLOSURE	Filing Date	04/26/2005		
•	STATEMENT BY AF	PPLICANT	First Named Inventor	Behr		
	•		Art Unit	1655		
	(Use as many sheets as ne	cessary)	Examiner Name	Qiuwen MI		
Sheet	4	of 11	Attorney Docket Number	41313-1004		

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1	US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-	•				
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			·		
		US-					
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,				
Initials*	No.'	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵			
	AZ	JP 2003 201212	07-18-2003	Inomata et al.					
	BA	JP 2003 201229	07-18-2003	Inomata et al.					
_	BB	WO 98/49267	11-05-1998	Raskin					
	ВС	WO 00/07437	02-17-2000	Raskin					
	BD	WO 00/51562	09-08-2000	Inomata					

Examiner	Date	
Signature	Considered	
<u></u>		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language of Translation is attached.

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

	Substitute for form 1449A/PTO		Complete if Known			
			Application Number	10/533,025		
	INFORMATION DISCL	OSURE.	Filing Date	04/26/2005		
;	STATEMENT BY APP	LICANT	First Named Inventor	Behr		
			Art Unit	1655		
	(Use as many sheets as necess	ary)	Examiner Name	Qiuwen MI		
Sheet	5	f 11	Attorney Docket Number	41313-1004		

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-		,			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			<u> </u>		
		US-			 -		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	BE	WO 00/62789	10-26-2000	Msika			
-	BF	WO 02/11745	02-14-2002	Kim et al.			
	BG	WO 02/34231	05-02-2002	Breton et al.			
	ВН	WO 02/34276	05-02-2002	Breton et al.			
	BI	WO 02/069992	09-12-2002	Cyr			

	1		•
Examiner	Date		
		1	
Signature	Considered		
	1		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO		Co	mplete if Known		
		Application Number	10/533,025		
1	NFORMATION DISC	CLOSURE	Filing Date	04/26/2005	
•	STATEMENT BY AF	PPLICANT	First Named Inventor	Behr	
			Art Unit	1655	
	(Use as many sheets as nec	cessary)	Examiner Name	Qiuwen MI	
Sheet	6	of 11	Attorney Docket Number	41313-1004	$\overline{}$

	_		U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where
	NO.	Number-Kind Code ^{2 (if known)}	MM-00-1111	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	<u> </u>	US-			
		US-			
		US-			
	<u> </u>	US-			
		US-			
		US-			
·		US-			
		US-	,		
		US-			
		US-			
		US-			
		US-	•		
		US-		,	
		US-			
		US-	•		
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
	BJ	RU 2141328	11-20-1999	Chenko et al.			
	ВК	WO 03/035092	05-01-2003	Kim			

Examiner	Date	
Signature	Considered	
	1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 03/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/533,025 INFORMATION DISCLOSURE Filing Date 04/26/2005 STATEMENT BY APPLICANT **First Named Inventor** Behr Art Unit 1655 (Use as many sheets as necessary) **Examiner Name** Qiuwen MI Attorney Docket Number 11 41313-1004 Sheet

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	BL	Y. Allanore et al., (2003), J. Rheumatol., 30(1):68-73			
	ВМ	A. Berton et al., (2000), Matrix Biol, 19(2):139-146			
	BN	S. Bosset et al., (2003), Br J Dermatol., 148(4):770-8			
·	ВО	P. Brenneisen et al., (2002), Ultraviolet-B irradiation and matrix metalloproteinases: from induction via signaling to initial events. Ann NY Acad. Sci., 973:31-43			
	ВР	M. Demeule et al., (2000), Biochimica et Biophysica Acta. Matrix metalloproteinase inhibition by green tea catechins, pp. 51-60			
	BQ	B. Dubois et al., (1998), Regulation of Gelatinase B (MMP-9) in Leukocytes by Plant Lectins, FEBS Lett., 427:275-278			
	BR	SE Fligiel et al., (2003), J. Invest Dermatol., 120(5):842-8			
	BS	D.C. Gervasi et al., (1996), Carbohydrate-Mediated Regulation of Matrix Metalloproteinase-2 Activation in Normal Human Fibroblasts and Fibrosarcoma Cells, Biochem. Biophys. Res. Comm., 228:530-538			
	ВТ	Y. Hojima et al., (Mar 1983), Survey of plant inhibitors of polymorphonuclear leukocyte elastase, pancreatic elastase, cathepsin G, Hageman factor fragments, and other serine proteinases, Biochem Pharmacol, 32(6) 985-990			
		K.A. Homer et al., (1992), Inhibition of Peptidase and Glycosidase Activities of Porphyromonas-Gingivalis Bacteroides-Intermedius and Treponema-Denticola by Plant Extracts, Journal of Clinical Periodontology, 19:305-310			

Examiner	Date	
Signature	Consid	dered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Applaces. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Subs	titute for form 1449B/PTO			Complete if Known			
				Application Number	10/533,025		
INI	FORMATION DIS	CLOS	URE	Filing Date	04/26/2005		
STATEMENT BY APPLICANT				First Named Inventor	Behr		
				Art Unit	1655		
	(Use as many sheets as ne	cessary)		Examiner Name	Qiuwen MI		
Sheet	8	of	11	Attorney Docket Number	41313-1004	-J	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Γ ²			
	BV	N. Isnard et al., (2002), Biomed Pharmacother., July, 56(5):258-264				
	BW	S. Johansson et al., (2002), J. Nat Prod., 65:32-41				
	вх	M. Jonadet et al., (Jan-Mar 1986), [Flavonoids extracted from Ribes nigrum L. and Alchemilla vulgaris L.: 1. In vitro inhibitory activities on elastase, trypsin and chymotrypsin. 2. Angioprotective activities compared in vivo]., J. Pharmacol, 17(1)21-27.				
	BY	CM Keilty et al., (1994), FEBS Lett, 351:85-89				
	BZ	CM Keilty et al., (2002), J Cell Sci., 115:2817-2828				
	CA	Koch et al., (1991), Agents Actions, 34:350-7				
	СВ	Krupa and Mort (2000), Anal Biochem., 283(1):99-103				
	СС	J. Labat-Robert et al., (2000), Age dependent increase of elastase type protease activity in mouse skin. Effect of UV-irradiation, J. Photochem Photobiol B, 57(2-3):113-8				
	CD	K.K. Lee et a., (1999), Inhibitory Effects of 150 Plant Extracts on Elastase Activity and Their Anti-inflammatory Effects, International Journal of Cosmetic Science, Vol. 21, No. 2, pp. 71-82				
	CE	F. Lopez et al., (1994), Accumulation of a 22-kDa protein and its mRNA in the leaves of Raphanus sativus in response to salt stress or water deficit, Physiologia Plantarum, 91:605-614				

1 1	1	
Examiner	Date	
1	Considered	
Signature	I Considered	1

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Appleces. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Subs	titute for form 1449B/PTO			Complete if Known			
		•		Application Number	10/533,025		
INI	FORMATION DIS	CLOS	URE	Filing Date	04/26/2005		
ST	ATEMENT BY A	PPLIC	ANT	First Named Inventor	Behr		
`				Art Unit	1655		
	(Use as many sheets as ned	cessary)		Examiner Name	Qiuwen MI		
Sheet	9	of	11	Attorney Docket Number	41313-1004		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CF	WD McMillan et al., (1997), Circulation, 96:2228-2232	
	CG	MF Melzig et al., (Sept 1999), Inhibition of granulocyte elastase activity by caffeic acid derivatives, Pharmazie, 54(9) 712	
	СН	Nagase et al., (1998) Inhibitory Effect of Delphinidin from solanum Melongena on Human Fibrosarcoma HT-1080 Invasiveness in vitro, Planta Med., 64:216-219.	
	CI	Y. Nishimori et al., (2001), Degenerative alterations of dermal collagen fiber bindles in photodamaged human skin and UV-irradiated hairless mouse skin: possible effect on decreasing skin mechanical properties, J. Invest Dematol., 117(6): 1458-63	
	CJ	Obayashi et al., (1998), Nippon Keshonin Gijutsusha Kaishi, 32:272-279	
	СК	Paemen et al., (1996) Biochem. Pharm. 52:105-111	
	CL	D.H. Paper, (1998), Natural Products as Angiogenesis Inhibitors, Planta Medica, Vol. 64, No. 8, pp. 686-695	
	СМ	T. Reinheckel et al., (2001), Biol Chem, 382(5):735-741	
	CN	R. Roguet, (2002), Skin Pharmacol Appl Skin Physiol., 15 Suppl 1:1-3	
	СО	K. Sakuraoka et al., (1996), J Dermatol Sci, 12(3):232-237	

	·
Examiner	Date
Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments are the constant of time and constant this form and/or successions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Subs	titute for form 1449B/PTO	·		Complete if Known			
				Application Number	10/533,025		
IN	FORMATION DIS	CLOS	URE	Filing Date	04/26/2005		
ST	ATEMENT BY AF	PPLIC	ANT	First Named Inventor	Behr	_	
				Art Unit	1655	٦	
•	(Use as many sheets as nec	essary)		Examiner Name	Qiuwen MI		
Sheet	10	of	11	Attorney Docket Number	41313-1004	ノ	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
·	СР	B. Starcher et al., (1995), Ciba Found Symp, 192:338-46			
	cq	M. Szendroi et al., (1984), J. Invest Dermatol, 83:224-229			
	CR	K. Tsukahara et al., (2001), Biol Pharm Bull, 24(9):998-1003			
	cs	RE Watson et al., (1999), J. Invest Dermatol., 112(5):782-7			
	СТ	U. Wormser et al., (1997), Arch Dermatol Res., 289(12):686-691			
	cu	QL Ying et al., (July 1991), Inhibition of human leuccyte elastase by ursolic acid. Evidence for a binding site for pentacyclic triterpenes, Biochem J., 15:277 (pt 2) 521-526			
n -	cv	International Search Report from WO 2006/053415			
	cw	International Search Report from WO 2004/019961			
	сх	Office Action dated 10/06/2006 for U.S. Application No. 10/469,402	,		
	CY	Office Action dated 05/30/2007 for U.S. Application No. 10/469,402			

Examiner	-	Date	
Signature		Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO					Complete if Known			
					Application Number	10/533,025		
	INF	ORMATION D	ISCLOS	URE	Filing Date	04/26/2005		
	STA	ATEMENT BY	APPLIC	ANT	First Named Inventor	Behr		
(Use as many sheets as necessary)					Art Unit	1655		
					Examiner Name	Qiuwen MI		
<u> </u>	Sheet	11	of	11	Attorney Docket Number	41313-1004		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CZ	Office Action dated 02/27/2007 for U.S. Application No. 10/526,387	
	DA	Office Action dated 06/28/2007 for U.S. Application No. 10/526,387	_
	DB	Office Action dated 10/21/2007 for U.S. Application No. 10/526,387	ļ
		·	-

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.